Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study.

Date publication

février 2009

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MAYNADIE Marc

Tous les auteurs :
Lacombe F, Arnoulet C, Maynadie M, Lippert E, Luquet I, Pigneux A, Vey N, Casasnovas O, Witz F, Bene MC

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/18987664

Résumé

An early appreciation of treatment efficacy could be very useful in acute myeloblastic leukemia (AML), and a prognostic value has been suggested for the morphological assessment of decrease in blasts during induction therapy. More sensitive, multiparametric flow cytometry (FCM) can detect far lower blast counts, allowing for a precise and reliable calculation of blast cell decrease rate (BDR). Such a multiparametric FCM four-colours/single-tube protocol, combining CD11b, CD45-ECD and CD16-PC5, was applied to peripheral blood samples from 130 AML patients, collected daily during induction chemotherapy. Normalized blast cell percentages were used to calculate the relevant decrease slopes. Slope thresholds (-15), or the time required to reach 90% depletion of the peripheral blast load (5 days), was strongly associated with the achievement of complete remission (P

Référence

Leukemia. 2009 Feb;23(2):350-7